The lawsuit comes after Replimune investors witnessed a 77% collapse in the price of their shares on July 22 when the company announced that the Food and Drug Administration (FDA) had rejected its ...

Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...

Replimune said the agency had issued a complete response letter regarding the company’s biologics license application for RP1 ...

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Replimune Group, Inc. (NASDAQ: REPL) resulting from ...

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.

Each option has an exercise price of $9.75 per share, which is equal to the closing price of the Company's common stock on June 5, 2025. Replimune Announces Inducement Grants Under Nasdaq Listing ...

Replimune Group granted stock options and restricted shares to ten new non-executive employees as part of their incentive plan. Replimune Group, Inc., a clinical stage biotechnology company based ...

Replimune Group stock opened at $9.45 on Thursday. Replimune Group has a 12-month low of $6.44 and a 12-month high of $17.00. The stock has a market cap of $728.50 million, a P/E ratio of -3.08 ...

Research and development expenses included $4.5 million in stock-based compensation expenses for the fiscal fourth quarter and $18.4 million for the fiscal year ended March 31, 2025.